Humira (Adalimumab) is a biologic drug approved by the FDA to treat moderate to severe hidradenitis suppurativa (HS) in people 12 and older. It works by neutralizing tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks, to reduce inflammation.

Administration
- Initial loading dose
- read more

Humira (Adalimumab) is a biologic drug approved by the FDA to treat moderate to severe hidradenitis suppurativa (HS) in people 12 and older. It works by neutralizing tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks, to reduce inflammation.

Administration:
- Initial loading dose
- Followed by subcutaneous injections every week or every other week
- Available as a single-dose prefilled pen or syringe

Common Side Effects:
- Respiratory infections
- Headache
- Redness or irritation at injection sites
- Rash

Serious Side Effects:
- Severe allergic reactions
- Potentially fatal infections
- New or worsening heart failure
- Lupus-like syndrome
- Demyelinating disease (e.g., multiple sclerosis)
- Increased risk of certain cancers, such as lymphoma

For more details, you can visit the Humira page on myHSteam: [Humira — AbbVie](https://www.humira.com).

 This AI-generated response comes from myHSteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Humira (Adalimumab) for Hidradenitis suppurativa | myHSteam

How Do Biologics Treat Hidradenitis Suppurativa? | myHSteam